Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $210
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $180
Analysts Conflicted on These Healthcare Names: Spruce Biosciences (OtherSPRB), Cigna (CI) and Axsome Therapeutics (AXSM)
Axsome Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $153
Baird Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $162
Truist Financial Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Strong Buy Rating for Axsome Therapeutics Driven by Product Performance and Pipeline Progress
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $176 to $210
Axsome Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), TG Therapeutics (TGTX) and Vertex Pharmaceuticals (VRTX)
Deutsche Bank Adjusts Axsome Therapeutics Price Target to $190 From $187, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC) and Axsome Therapeutics (AXSM)
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $210
Axsome Therapeutics (AXSM) Gets a Buy From Mizuho Securities
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $193
Axsome Therapeutics Price Target Raised to $193.00/Share From $190.00 by RBC Capital
Axsome Therapeutics Is Maintained at Outperform by RBC Capital
Axsome Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Alnylam Pharma (ALNY)